 So, the Cartitute IV trial was the first CAR T-cell trial that was addressing patients in second to fourth line of therapy. So, the first time it was a randomized trial where we looked whether CAR T-cells are better than standard of care in earlier lines of therapy. It was actually a comparison between CAR T-cell therapy and either Pomalidomide Velcadex or Daraptumoma Pomalidomidex. And after the short pritching therapy, patients received silt-cell infusion. And the results were that the patients that had received, or were supposed to receive silt-cell, had a progression-free survival that was not reached in the median after 16 months, whereas in the conventional arm with standard of care, the progression-free survival was 11.3 months. So, it was clearly, clearly better, the silt-cell arm. So, the main side effects were neutropenia, thrombocytopenia, but that happened in both arms. Also, the infection rate was about the same in both arms. Also, secondary tumors were about the same. And there were more deaths due to COVID in the silt-cell arm. So, it's very important. I think this is an important message to everybody. If you receive CAR T-cell therapy, you are very vulnerable to infections and COVID still plays a role in CAR T-cell-free patients. And then there's the typical CAR T-cell side effects. So, cytokine release syndrome, neurotoxicity, which was not very frequent. It was about 70% grade 1, 1% grade 2 CRS, neurotoxicity about 20% in total, and only about 2% or 2.8% grade 3. What they had in addition was the so-called non-icons neurotoxicity. So, some patients had nerve palsies or Bells palsy happen in 16 patients. Some patients had some form of neuropathy, but that was only about five patients out of 200. And only one patient, fortunately enough, had this kind of Parkinson-like syndrome. And that was rather mild. And I think the reasons why these side effects were less severe than when compared to Cartitude 1 is that we had a better bridging therapy. So, it's important if you go for CAR T-cell therapy to really try to control the disease before you give the CAR T-cells. Then it's better tolerated and more effective. Yeah, I think it's for the first time and we are all very optimistic that we will get approval for second, third and fourth line using CAR T-cells. I think this is something we should really aim for. And then the next step will be whether the companies will be able to provide sufficient number of CAR T-cells and whether our healthcare systems are prepared to pay for it. But I think it's a real hope for our patients because what we see now in these... because we are getting really good in first line therapy but it's getting more and more difficult to treat patient in second and third line and here we have a completely new option. And I think that's... I'm really so happy that we have it.